Navigation Links
Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant
Date:3/5/2009

-Company Provides Update on Cash Position-

-Biologics License Application for Wrinkles/Nasolabial Folds Indication Expected To Be Filed Within Two Weeks-

EXTON, Pa., March 5 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. (Amex: ILE) announced today positive top-line efficacy results from a Phase II/III clinical study (Study IT-A-008) of the Isolagen Therapy(TM) for the treatment of moderate to severe acne scars. The study met all primary efficacy endpoints and was statistically significant, making this a major clinical milestone for the Company.

"This is very exciting, positive data which continues to support the potential of the Isolagen Therapy as a platform technology for aesthetic and therapeutic indications," said Declan Daly, President and Chief Executive Officer of Isolagen, Inc. "There is a great need globally for the treatment of acne scars and we believe that the Isolagen Therapy has a significant role to play in this largely untapped market."

The Phase II/III, placebo-controlled study investigating the efficacy and safety of Isolagen Therapy(TM) for the treatment of moderate to severe acne scars evaluated a total of 109 people at seven clinical sites across the United States. In the study, both the Patient and Evaluator assessments met the co-primary endpoints and were statistically significant, achieving p-values of 0.000011 and 0.016, respectively (p-values less than or equal to 0.05 are considered statistically significant).

With respect to the Patient assessments, 43 percent of patients reported a response to the Isolagen Therapy-treated side of the face, while 18 percent of patients reported a response on the placebo-treated side of the face. With respect to the Evaluator assessments, evaluators reported that 59 percent of patients responded on the Isolagen
'/>"/>

SOURCE Isolagen, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study
2. Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Spherix Reports Second Quarter Earnings
5. Tapestry Reports Second Quarter 2007 Results
6. Callisto Reports on Second-Quarter 2007 Milestones
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
10. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
11. Biopure Reports on Meeting with the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014  Avanir Pharmaceuticals, Inc. (NASDAQ: ... overview of the company at the Morgan Stanley Global Healthcare ... , Presentation date: Tuesday September 9, 2014 , Presentation ... webcast and 30-day archive of this presentation will be available ... Inc. Avanir Pharmaceuticals, Inc. is a biopharmaceutical company ...
(Date:9/2/2014)... , September 2, 2014 Today, ... (NYSE: WLP ), Tekmira Pharmaceuticals Corporation (NASDAQ: ... ZTS ), Sanofi SA (NYSE: SNY ) ... these notes ahead of publication. To reserve complementary membership, ... ,-- ,WellPoint Inc. Research Reports ,WellPoint Inc. (WellPoint) posted ...
(Date:9/2/2014)... DUBLIN , Sept. 2, 2014 Actavis ... the U.S. Food and Drug Administration (FDA) has accepted ... an investigational drug for the treatment of diarrhea and ... Irritable Bowel Syndrome (IBS-D).  Actavis, NDA for eluxadoline has ... Logo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO "The ...
Breaking Medicine Technology:Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 2Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 3Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 4Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 5Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 6Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 2Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 3Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 4
... Australia, Sept. 26 Hospira, Inc. (NYSE: ... injectable pharmaceuticals, today announced that it has received ... biosimilar filgrastim product, Nivestim™. Nivestim ... including the prevention of febrile neutropenia (FN) and ...
... Pharma US, Inc. ("Astellas") announced results of a ... comparable to placebo in causing a >15% decrease ... in subjects with asthma or chronic obstructive pulmonary ... perfusion imaging (MPI) studies(1). Results were presented during ...
Cached Medicine Technology:Hospira Receives TGA Approval for Nivestim™, Australia's First Biosimilar Filgrastim 2Hospira Receives TGA Approval for Nivestim™, Australia's First Biosimilar Filgrastim 3Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD) Presented as Late-Breaker at American Society of Nuclear Cardiology 2010 2Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD) Presented as Late-Breaker at American Society of Nuclear Cardiology 2010 3Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD) Presented as Late-Breaker at American Society of Nuclear Cardiology 2010 4Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD) Presented as Late-Breaker at American Society of Nuclear Cardiology 2010 5
(Date:9/2/2014)... Breast cancer patients treated with lumpectomy followed by ... had bilateral mastectomy, according to a large study ... of Medicine and the Cancer Prevention Institute of ... California women with the disease is the first ... most common surgical interventions: bilateral mastectomy (the removal ...
(Date:9/2/2014)... Germany, September 2, 2014 In a large ... researchers found that mild cognitive impairment (MCI) occurred ... mellitus type 2. Interestingly, this strong association was ... in older participants (66-80 years) the association vanished. ... of Alzheimer,s Disease . , The concept of ...
(Date:9/2/2014)... the emergency department within a few days of discharge do ... have lost trust in other parts of the health care ... today in Annals of Emergency Medicine ( "Return ... , "When asked why they did not follow up ... too severe to wait until their scheduled appointment or being ...
(Date:9/2/2014)... The Dream2Walk Foundation along with Gas Monkey ... 2014 during Spinal Cord Injury Awareness Month featuring full band ... Chuck Ligon. Linear Automotive will be there hosting a Hot ... open at 2pm. The car show is Pre 1964 only, ... to the concert. There will be trophies for top 3 ...
(Date:9/2/2014)... Kathleen Doheny HealthDay ... The U.S. obesity epidemic is a driving force behind the ... study. Researchers looked at data from five national surveys ... increase in diabetes over time could be explained by factors ... U.S. adults. The investigators found that the prevalence of ...
Breaking Medicine News(10 mins):Health News:Breast cancer patients with bilateral mastectomy don't have better survival rates 2Health News:Breast cancer patients with bilateral mastectomy don't have better survival rates 3Health News:Breast cancer patients with bilateral mastectomy don't have better survival rates 4Health News:Diabetes mellitus and mild cognitive impairment: Higher risk in middle age? 2Health News:Discharged patients return to the ER because 'better safe than sorry' 2Health News:Gas Monkey Hosts Concert in Dallas Benefiting Dream2Walk Foundation with Linear Automotive 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 3
... As the U.S. immigrant population grows it will be necessary ... have access to health insurance coverage, or who face other ... (ACP) said in a new policy paper released today at ... and Access to Health Care discusses the challenges immigrants face ...
... , THURSDAY, April 7 (HealthDay News) -- After hooking up ... the computer to "read" the thoughts of disabled patients, thereby ... The researchers are hoping the breakthrough will one day lead ... world around them. "We have been fundamentally interested in ...
... NY) For many types of cancer, the original tumor ... a tiny subpopulation of cells from the primary tumor to ... too often kills the patient. Now, researchers at ... have identified two molecules that enable cancer to spread inside ...
... the American Thyroid Association (ATA) on outpatient radioiodine (131I) ... the safety of patients, their families, and the public. ... issue of Thyroid , a peer-reviewed journal published ... ATA recommendations are available free online at www.liebertpub.com/thy ...
... WEDNESDAY, April 6 (HealthDay News) -- Long-term users of the ... a new study. Brain scans showed an approximate 10 ... lower proportion of overall gray matter among long-term ecstasy users, ... who use ecstasy can develop serious memory problems, so a ...
... Virtual reality and other video games can significantly improve ... Michael,s Hospital. Patients who played video games, such ... likely to show improvements in arm motor function compared to ... is a promising and potentially useful alternative to enhance motor ...
Cached Medicine News:Health News:Physicians call for better access to health care for immigrants 2Health News:Physicians call for better access to health care for immigrants 3Health News:Scientists Use Computer to 'Read' Human Thoughts 2Health News:Scientists Use Computer to 'Read' Human Thoughts 3Health News:Molecules identified that help propel cancer metastasis 2Health News:New radiation treatment practice recommendations for thyroid disease 2Health News:Long-Term Ecstasy Users at Risk for Brain Damage, Study Warns 2Health News:Video games effective treatment for stroke patients: study 2
... The WideBiter Punch series facilitates fast ... recreating a smooth, anatomically shaped meniscal rim. ... low profile to access even the tightest ... Arthrex California, Inc., 20 years of engineering ...
... The WideBiter Punch series facilitates fast and ... a smooth, anatomically shaped meniscal rim. The ... profile to access even the tightest joint ... California, Inc., 20 years of engineering experience ...
... facilitates fast and effective resection of meniscal ... meniscal rim. The flat, crescent-shaped tip has ... the tightest joint spaces. Made in the ... of engineering experience in arthroscopy hand instrument ...
... Punch series facilitates fast and effective resection ... anatomically shaped meniscal rim. The flat, crescent-shaped ... access even the tightest joint spaces. Made ... 20 years of engineering experience in arthroscopy ...
Medicine Products: